ResMed Inc. (NYSE:RMD)’s share price traded up 1.4% during trading on Wednesday . The company traded as high as $64.95 and last traded at $64.91, with a volume of 240,358 shares trading hands. The stock had previously closed at $64.02.

A number of equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday, April 27th. BMO Capital Markets reissued a “hold” rating on shares of ResMed in a research note on Wednesday, April 27th. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research note on Wednesday, April 27th. Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 27th. Finally, Canaccord Genuity reissued a “hold” rating on shares of ResMed in a research note on Wednesday, April 27th. Three analysts have rated the stock with a sell rating, six have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. ResMed presently has an average rating of “Hold” and a consensus price target of C$59.69.

The company has a market capitalization of $9.05 billion and a P/E ratio of 26.41. The firm has a 50 day moving average of $60.75 and a 200-day moving average of $58.01.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Tuesday, April 26th. The company reported $0.68 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by $0.01. The company had revenue of $453.90 million for the quarter, compared to analyst estimates of $455.32 million. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.65 earnings per share. On average, analysts forecast that ResMed Inc. will post $2.66 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 16th. Investors of record on Thursday, May 19th were issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 1.86%. The ex-dividend date was Tuesday, May 17th.

In related news, Director Peter C. Farrell sold 20,000 shares of the company’s stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of C$55.90, for a total transaction of C$1,118,000.00. Following the completion of the sale, the director now directly owns 367,978 shares of the company’s stock, valued at approximately C$20,569,970.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Pendarvis sold 6,000 shares of the company’s stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of C$56.02, for a total transaction of C$336,120.00. Following the sale, the insider now directly owns 80,287 shares of the company’s stock, valued at C$4,497,677.74. The disclosure for this sale can be found here.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in ResMed by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 10,244,386 shares of the company’s stock valued at $550,022,000 after buying an additional 212,360 shares in the last quarter. Schroder Investment Management Group boosted its position in ResMed by 141.5% in the fourth quarter. Schroder Investment Management Group now owns 1,084,409 shares of the company’s stock valued at $58,222,000 after buying an additional 635,354 shares during the last quarter. American Capital Management Inc. boosted its position in ResMed by 2.3% in the fourth quarter. American Capital Management Inc. now owns 610,845 shares of the company’s stock valued at $32,796,000 after buying an additional 13,545 shares during the last quarter. Principal Financial Group Inc. boosted its position in ResMed by 3.4% in the fourth quarter. Principal Financial Group Inc. now owns 449,971 shares of the company’s stock valued at $24,159,000 after buying an additional 14,894 shares during the last quarter. Finally, Winton Capital Group Ltd boosted its position in ResMed by 13.7% in the fourth quarter. Winton Capital Group Ltd now owns 437,623 shares of the company’s stock valued at $23,496,000 after buying an additional 52,824 shares during the last quarter.

ResMed Inc is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.